SHOP ANTIBODIEs
Free Shipping in the U.S. for orders over $1000. Shop Now>>
Antibodies are among the most commonly employed biological research reagents – tools used primarily to identify and/or isolate molecules of interest. However, if antibodies are not specific, they can also be the cause of many problems regarding data interpretation and may hinder researcher’s abilities to reach unambiguous conclusions.
Monospecific antibody offers several advantages due to their high specificity, making them an important tool in research, diagnostics, and therapy. Monospecific antibodies provide consistent and reproducible results in experiments because they bind uniformly to their specific target. However, it has been shown that not all monoclonal antibodies are monospecific, so robust antibody specificity testing is critical.
The use of human protein microarrays has set new quality standards in the evaluation of antibody cross-reactivity, and enables the identification of high-quality, high-specificity antibodies that are suitable for robust scientific investigations, grant proposals and commercialization. Additionally, protein arrays can help determine the sensitivity of antibodies by quantifying their ability to detect target proteins at varying concentrations. The HuProt™ Human Microarray from CDI Labs is currently the largest collection of human proteins available, representing ~80% of the human proteome, and can provide the most comprehensive picture of antibody cross-reactivity available today. Additionally, the proteins spotted on HuProt arrays are robustly expressed, so array analysis can give a clear profile of cross-reactivity across proteins that are selectively expressed in a wide range of cell lines. Antibodies validated using HuProt microarray technology profoundly impact data accuracy, reliability, and specificity; factors of paramount importance to scientific research and innovation.
~80% of the human proteome, and can provide the most comprehensive picture of antibody cross-reactivity available today. Additionally, the proteins spotted on HuProt arrays are robustly expressed, so array analysis can give a clear profile of cross-reactivity across proteins that are selectively expressed in a wide range of cell lines. Antibodies validated using HuProt microarray technology profoundly impact data accuracy, reliability, and specificity; factors of paramount importance to scientific research and innovation.
Antibody specificity is evaluated using the CDI Labs HuProt™ Human Proteome Microarray and subsequently analyzed with Microarray Analysis Antibody specificity is evaluated using the CDI Labs HuProt™ Human Proteome Microarray and subsequently analyzed with GenePix Pro Image Acquisition and Analysis Software (the benchmark tool for the acquisition and analysis of microarray images). Thousands of GenePix data points from the microarray are analyzed in terms of signal strength and ranked accordingly. The top “hits” are identified by cross-reference to the array map which stores the exact location of each protein. If the expected target is ranked #1 and the S-Score (the difference between Rank #1 and #2) meets specific thresholds, then the antibody can be considered monospecific.
HuProt validated antibodies from NeoBiotechnologies are high-quality monospecific antibodies which demonstrate high affinity to their intended target, while exhibiting no statistically significant cross-reactivity.
CDI Labs offers transformational tools and services that empower researchers to unravel the connection between autoantibodies and disease. CDI offers the HuProt™ Human Proteome Microarray – the most comprehensive collection of correctly-folded, full-length human proteins, and VirScan®, HuScan®, and MouseScan™ Phage ImmunoPrecipitation Sequencing (PhIP-Seq) services. Application areas include autoantibody seromics, target identification and antibody specificity validation.
